Dijana Djureinovic

Development of [111In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages

Anna E. Strong, Erika Belitzky, Ayla Vaughn Embs, Samantha Katz et autres

PURPOSE: High tumor-associated macrophage (TAM) abundance is associated with poorer prognoses across many cancers, including renal cell carcinoma (RCC). CD68 is an established clinical biomarker for macrophages in patient tissues and is also expressed in mouse macrophages, making it an attractive target …

us (code pays fourni par la source)

CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells

Dijana Djureinovic, Jacqueline E. Mann, Jasmine I. Caulfield, Dorin Bar‐Ziv et autres

Immune checkpoint blockade (ICB) has improved survival for patients with metastatic renal cell carcinoma (RCC), but there remains a need to overcome resistance mechanisms. CD40 agonists increase anti-tumoral immunity, but limited data are available on their activity in RCC. We evaluated CD40 …

us (code pays fourni par la source)

CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. Djureinovic et al.

Dijana Djureinovic

CD40 agonism was evaluated in combination with immune-checkpoint blockade in Renca. Single cell RNA-sequencing was performed on tumor and TILs isolated 24 hours after two treatments. Digital count matrices were analyzed to identify cell types and frequencies of the different cell populations …

CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. Djureinovic et al.

Dijana Djureinovic

CD40 agonism was evaluated in combination with immune-checkpoint blockade in Renca. Single cell RNA-sequencing was performed on tumor and TILs isolated 24 hours after two treatments. Digital count matrices were analyzed to identify cell types and frequencies of the different cell populations …

1266 Spatial profiling of melanoma brain metastases exhibit elevated neural cell adhesion molecule 1 (NCAM1) protein expression and associations with immune microenvironment and treatment response

David G. Su, Noam Savion Gaiger, David A. Schoenfeld, Mingze Dong et autres

Background Melanoma brain metastases (MBM) affect approximately 60% of patients with metastatic melanoma and exhibit distinct molecular and immune features compared to extracranial metastases (ECM). 1 2 Prior studies have demonstrated a unique immune microenvironment in MBM, including increased CD8+ T-cell infiltration …

us (code pays fourni par la source)

Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma

Thazin Nwe Aung, Matthew Liu, David G. Su, Saba Shafi et autres

Importance: Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin-stained slides is prone to interobserver variability, leading to inconsistent clinical decisions. Therefore, development of newer TIL scoring …

us, se, es, au, ro, rs, gb, pt, hu, il, be, it, tr, de, at, si, ch, pl (code pays fourni par la source)

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases

Sarah Ann Weiss, Dijana Djureinovic, Wei Wei, Thuy Thanh Thi Tran et autres

PURPOSE: Anti-vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis. METHODS: We conducted a two-institution phase II trial of bevacizumab and pembrolizumab in patients with untreated melanoma …

us (code pays fourni par la source)

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma

David A. Schoenfeld, Dijana Djureinovic, David G. Su, Lin Zhang et autres

The cytokine IL-18 has immunostimulatory effects but is negatively regulated by a secreted binding protein, IL-18BP, that limits IL-18's anticancer efficacy. A decoy-resistant form of IL-18 (DR-18) that avoids sequestration by IL-18BP while maintaining its immunostimulatory potential has recently been developed. Here, …

us (code pays fourni par la source)

GP100 expression is variable in intensity in melanoma

Jacqueline E. Mann, Nitzan Hasson, David G. Su, Adebowale Adeniran et autres

Drugs or cellular products that bind to gp100 are being investigated for treatment of cutaneous melanoma. The relative specificity of gp100 expression in melanocytes makes it an attractive target to harness for therapeutic intent. For example, Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 …

us (code pays fourni par la source)

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma

David G. Su, Dijana Djureinovic, David A. Schoenfeld, Bernadette V. Marquez-Nostra et autres

PURPOSE: Melanocortin-1 receptor (MC1R) plays a critical role in human pigmentation and DNA repair mechanisms. MC1R-targeting agents are being investigated in clinical trials in patients with melanoma, yet large studies investigating the rate and degree of MC1R expression in primary and metastatic …

us (code pays fourni par la source)

Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma

David G. Su, David A. Schoenfeld, Wael Ibrahim, Raysa Cabrejo et autres

BACKGROUND: Desmoplastic melanoma (DM) is a rare melanoma subtype characterized by dense fibrous stroma, a propensity for local recurrence, and a high response rate to programmed cell death protein 1 (PD-1) blockade. Occult sentinel lymph node positivity is significantly lower in both …

us (code pays fourni par la source)

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Dijana Djureinovic, Sarah Ann Weiss, Irina Krykbaeva, Rihao Qu et autres

BACKGROUND: Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects of this three-drug regimen in …

us (code pays fourni par la source)